Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer

RIDGEFIELD, CT – (July 28, 2021) – Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer. “TP-317 is a first-in-class Resolvin E1 therapy that offers a transformative new […]

Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board

RIDGEFIELD, CT – (July 8, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans. The company’s lead program, TP-317, is a first-in-class Resolvin E1 […]

Thetis Pharmaceuticals Announces Completion of Pre-IND Meeting with FDA for Development of its Resolvin E1 Candidate, TP-317, for Inflammatory Bowel Disease

TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease RIDGEFIELD, CT – (January 20, 2021) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it completed a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration […]

Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis

Thetis’ drug candidate TP-317 is a first-in-class small molecule oral therapy in development for inflammatory bowel disease (IBD) RIDGEFIELD, CT – (December 14, 2020) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it has received U.S. Food and Drug Administration orphan drug designation for TP-317 […]